Artigos

3- Wu, J.J.; Huang, D.B; et all.; “Thalidomide: dermatological indications, mechanisms of action and side-effects”; British Journal of Dermatology 2005, 153, pp254-273

4- Teo, Steve K.; Stirling, Davis I.; Zeldis, Jerome B.; “Thalidomide as a novel therapeutic agent: neu uses for na old product”; Drug Discovery Today, Janeiro 2005, Vol. 10, N. 2; pp107-115

5- Pridgeon, Simon; Drake, Marcus; “Thalidomide and its use in renal and prostate cancer”; Cancer Therapy 2005, Vol 3, 65-76

6- Steven, K. Teo; “Properties of Thalidomide and its Analogues: Implications for Anticancer Therapy”, 2005; The AAPS Journal; 7 (1) Article 3

7- G. Wells, Peter; et al; “Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species”; Toxicology and Applied Pharmacology 207 (2005), S354-S366

8- Chung, Francisco; Lu, Jun; D. Palmer, Brian; Kestell, Philip; Browett, Peter; C. Baguley, Bruce; Tingle, Malcolm; Ching, Lai-Ming; “Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma pacients; Clinical Cancer Research, 2004, Vol.10, 5949-5956

9-Dimopoulos, Meletios A.; Eleutherakis-Papaiakovou, Vagelis; “Adverse Effects of Thalidomide Administration in Patients with neoplastic Diseases”; The American Journal of Medicine, Outubro 2004, Vol.117, pp508-514

10- Lu, Jun; Helsby, Nuala; D. Palmer, Brian; Tingle, Malcolm; C. Baguley, Bruce; Kestell, Philip; Ching, Lai-Ming; “Metabolism of Thalidomide in Liver Microsomes of Mice, Rabbits, and Humans, 2004, Journal of Pharmacology And Experimental Therapeutics 310:571-577

11- Cerny, Thomas; Gillesen, Silker; von Moos, Roger; Stolz, Rabel; “Thalidomide: from tragedy to promise”; Swiss Medical Weekly 2003; 133:77-87

12- J Perri III, Anthony; Hsu, Sylvia; “A review of thalidomide’s history and current dermatological applications; Dermatology Online Journal, 2003, 9 (3):5

13- Borges, Larissa; Froehlich, Pedros; “Talidomida – novas perspectivas para utilização como antiinflamatório, imunossupressor e antiangiogênico”; Revista da Associação Médica Brasileira, vol.49 no.1 São Paulo Jan./Mar. 2003

14- Gordon, J N; Goggin, P M; “Thalidomide and its derivatives: emerging from the wilderness”; Postgraduate Medical Journal 2003;79:127-132

15- Ando, Yuichi; Fuse, Eiichi; D. Figg, William ; “Thalidomide metabolism by the CYP2C Family”, 2002, vol.8, 1964-1973

16- Richardson, Paul; Hideshima, Teru; Anderson, Kenneth; “Thalidomide: Emerging Role in Cancer Medicine”; Annual Review Medicine 2002; 53:629-57

17- GE, Diggle; “Thalidomide: 40 years on”; International Journal of Clinical Practice, 2001, 55(9):627-31

18- D. Stephens, Trent; J.W. Bunde, Carolyn; J. Fillmore, Bradley; “Mechanism of Action in Thalidomid Teratogenesis”; Biochem Pharmacol., 2000, 15;59(12):1489-99

19- Shek, Lynette Pei-Chi; Lee, Yoke Sun; Lee, Bee Wah; “Thalidomide Responsiveness in an Infant With Behçet's Syndrome”; Pediatrics, Vol.103, Nº6 Junho 1999, pp1295-1297

20- Parman, Toufan; J. Wiley, Michael; G. Wells, Peter; “Free-radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenecity”; Nature America, 1999, vol.5, nº5

21- Smithells, D.; “Does thalidomide cause second generation birth defects?”; Drug Safety, 1998 Nov; 19(5):339-41

22- Liu, Ling; G. Wells, Peter; “DNA oxidation as a potencial mechanism mediating drug-induced birth defects: phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2’-deoxiguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues”; Free Radical Biology & Medicine, 1995, vol.19, nº5